Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

A trial date was set for a federal civil suit that claims Publix fueled the country's opioid epidemic. The National ...

Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...

Here's why people alleging Purdue Pharma's opioids harmed them may not see much of the proposed $7.4 billion settlement in a bankruptcy case.

A multidisciplinary team of University of Cincinnati Cancer Center researchers is leading a new clinical trial aimed to ...

The lawsuit claims Publix opioid sales increased while sales at competitors declined after they settled similar lawsuits. The trial is set for November in an Atlanta federal court and could have ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...